Previous Close | 61.09 |
Open | 61.58 |
Bid | 0.00 x 4000 |
Ask | 0.00 x 1300 |
Day's Range | 61.38 - 62.05 |
52 Week Range | 57.17 - 74.12 |
Volume | |
Avg. Volume | 7,126,265 |
Market Cap | 77.772B |
Beta (5Y Monthly) | 0.39 |
PE Ratio (TTM) | 10.61 |
EPS (TTM) | 5.84 |
Earnings Date | Apr 27, 2022 - May 02, 2022 |
Forward Dividend & Yield | 2.92 (4.89%) |
Ex-Dividend Date | Jun 14, 2022 |
1y Target Est | 69.48 |
If you want to invest in profitable healthcare companies in this bear market, these all look like good bets.
FOSTER CITY, Calif., August 09, 2022--Gilead Sciences, Inc. (Nasdaq: GILD), GLAAD, the Human Rights Campaign (HRC), the National Black Justice Coalition (NBJC), the National Center for Lesbian Rights (NCLR) and NMAC today announced immediate action in response to the emerging monkeypox virus (MPV) outbreak, which is disproportionately impacting the LGBTQ+ community, particularly men who have sex with men (MSM), as well as those who are living with HIV. Gilead will provide up to $5 million in glo
Drugmaker Gilead Sciences plans to announce on Tuesday that it will provide up to $5 million in grants to help a coalition of LGBTQ+ and human rights advocacy groups craft public health responses to monkeypox outbreaks, the company said. The World Health Organization and the United States have declared monkeypox a public health emergency. The Human Rights Campaign (HRC), GLAAD, the National Black Justice Coalition, and the National Center for Lesbian Rights are each receiving $350,000 from Gilead for public education toward preventing and treating the virus.